JNJ · News · 20261108N

Prostate Cancer Immunotherapy Progress

JOHNSON & JOHNSON · 2026-11-08 · Importance 17 · Surprise 24

Johnson & Johnson reported Phase 1 results for a dual-antigen bispecific regimen combining pasritamig and JNJ-9401, which targets the prostate cancer proteins KLK2 and PSMA to activate T cells. In the 15-patient study, 73% achieved PSA reductions of at least 50%, while nearly half achieved reductions of at least 90%. The report described responses as deep and sustained with dosing every six weeks, and noted an encouraging safety profile and potential for outpatient administration. The combination is advancing to Phase 3.

Key facts

• The pasritamig and JNJ-9401 combination showed an encouraging safety profile, with findings indicating potential for outpatient dosing as it advances to Phase 3. source
• In a Phase 1 study, 73% (11 of 15 patients) achieved PSA reductions of at least 50% with the pasritamig and JNJ-9401 combination. source
• In the Phase 1 study of the pasritamig and JNJ-9401 combination, nearly half of patients achieved PSA reductions of at least 90%. source
• The pasritamig and JNJ-9401 dual-antigen-targeted bispecific regimen targets the prostate cancer proteins KLK2 and PSMA and uses complementary signals to activate T cells against cancer. source